1
Lymphomas
February 2015
This bulletin covers aspects of lymphomas and should be of interest to multidisciplinary teams working in
this area.
Sections can include:
 Combined Modality Therapies
 Drug & Biological Therapies
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Stem Cell Transplantation
 Supportive Care & Symptom Management
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of available
online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you would
like to request a print copy, please submit your request online at www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is not
intended to be comprehensive. Professional judgment should be exercised when appraising the material.
The Library takes no responsibility for the wording, content and accuracy of the information supplied,
which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the
content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
1
2
General
Castillo JJ, Ghobrial IM and Treon SP. (2015). Biology, prognosis, and therapy of waldenstrom
macroglobulinemia. Cancer Treatment & Research 165,177-195.
Corradini P, Marchetti M, Barosi G, et al. (2014). SIE-SIES-GITMO guidelines for the management of
adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. Annals of
Oncology 25,12:2339-2350.
DeSimone JA, Sodha P, Ignatova D, et al. (2015). Recent advances in primary cutaneous T-cell
lymphoma. Current opinion in oncology 27,2:128-133.
Hitz F, Diem S, Haile SR, et al. (2014). Outcome of mantle cell lymphoma patients treated at a single
institution over the past decade. Hematological oncology 32,4:192-196.
Khan L, Hodgson D, Sun A, et al. (2015). A single institution experience of extranodal natural killer/T
cell lymphoma of nasal type. Leukemia & lymphoma 56,1:80-84.
Kritharis A, Sharma J and Evens AM. (2015). Current therapeutic strategies and new treatment
paradigms for follicular lymphoma. Cancer Treatment & Research 165,197-226.
Maddocks K and Blum KA. (2015). Treatment strategies in mantle cell lymphoma. Cancer Treatment
& Research 165,251-270.
Riemens A, Bromberg J, Touitou V, et al. (2015). Treatment strategies in primary vitreoretinal
lymphoma: a 17-center European collaborative study. JAMA Ophthalmology 133,2:191-197.
Skarbnik AP and Goy AH. (2015). Mantle cell lymphoma: state of the art. Clinical Advances in
Hematology & Oncology 13,1:44-55.
Combined Modality Therapies
Abbott S, Nikolousis E and Badger I. (2015). Intestinal lymphoma-a review of the management of
emergency presentations to the general surgeon. International journal of colorectal disease 30,2:151157.
Chen YB, Batchelor T, Li S, et al. (2015). Phase 2 trial of high-dose rituximab with high-dose
cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide
autologous stem cell transplantation in patients with central nervous system involvement by nonHodgkin lymphoma. Cancer 121,2:226-233.
Frosch Z, Luskin MR, Landsburg DJ, et al. (2015). R-CHOP or R-HyperCVAD With or Without
Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma. Clinical
lymphoma, myeloma & leukemia 15,2:92-97.
Fruchart C, Tilly H, Morschhauser F, et al. (2014). Upfront consolidation combining yttrium-90
ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients
with diffuse large B cell lymphoma. Biology of Blood & Marrow Transplantation 20,12:1905-1911.
2
3
Persky DO, Miller TP, Unger JM, et al. (2015). Ibritumomab consolidation after 3 cycles of CHOP
plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood
125,2:236-241.
Tsai HJ, Lin SF, Chen CC, et al. (2015). Long-term results of a phase II trial with frontline concurrent
chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/Tcell lymphoma. European journal of haematology 94,2:130-137.
Drug & Biological Therapies
Arnason JE, Luptakova K, Rosenblatt J, et al. (2015). Yttrium-90 ibritumomab tiuxetan followed by
rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not
candidates for autologous stem cell transplant. Acta Haematologica 133,4:347-353.
Bouabdallah K, Furst S, Asselineau J, et al. (2015). 90Y-ibritumomab tiuxetan, fludarabine, busulfan
and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with
advanced and high-risk B-cell lymphomas. Annals of Oncology 26,1:193-198.
Fowler NH, Davis RE, Rawal S, et al. (2014). Safety and activity of lenalidomide and rituximab in
untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncology 15,12:1311-1318.
Furtado M, Johnson R, Kruger A, et al. (2015). Addition of bortezomib to standard dose chop
chemotherapy improves response and survival in relapsed mantle cell lymphoma. British journal of
haematology 168,1:55-62.
Hoelzer D, Walewski J, Dohner H, et al. (2014). Improved outcome of adult Burkitt
lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter
trial. Blood 124,26:3870-3879.
Li H, Zhang HM, Chen LF, et al. (2015). Prophylactic lamivudine to improve the outcome of HBsAgpositive lymphoma patients during chemotherapy: A systematic review and meta-analysis. Clinics
& Research in Hepatology & Gastroenterology 39,1:80-92.
Michot JM, Canioni D, Driss H, et al. (2015). Antiviral therapy is associated with a better survival in
patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
American Journal of Hematology 90,3:197-203.
Njue A, Colosia A, Trask PC, et al. (2015). Clinical efficacy and safety in relapsed/refractory mantle
cell lymphoma: a systematic literature review. Clinical lymphoma, myeloma & leukemia 15,1:1-12.e7.
Pytlik R, Belada D, Kubackova K, et al. (2015). Treatment of high-risk aggressive B-cell non-Hodgkin
lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis
of the R-MegaCHOP-ESHAP-BEAM Trial. Leukemia & lymphoma 56,1:57-64.
Rossi G, Marcheselli L, Dondi A, et al. (2015). The use of anthracycline at first-line compared to
alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse
in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. American Journal of
Hematology 90,1:56-61.
Salihoglu A, Elverdi T, Karadogan I, et al. (2015). Brentuximab vedotin for relapsed or refractory
Hodgkin lymphoma: experience in Turkey. Annals of Hematology 94,3:415-420.
3
4
Steuter J, Bociek R, Loberiza F, et al. (2015). Utility of prechemotherapy evaluation of left ventricular
function for patients with lymphoma. Clinical lymphoma, myeloma & leukemia 15,1:29-34.
Straus DJ, Hamlin PA, Matasar MJ, et al. (2015). Phase I/II trial of vorinostat with rituximab,
cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with
relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell
transplantation. British journal of haematology 168,5:663-670.
Sun Z, Li X, Wu X, et al. (2014). Clinical analysis of chronic lung injury in patients with non-Hodgkin
lymphoma after CHOP chemotherapy. Tumour Biology 35,12:12601-12605.
Pathology, Staging, Polymorphisms & Biomarkers
Goyal A, Moore JB, Gimbel D, et al. (2015). PD-1, S-100 and CD1a expression in
pseudolymphomatous folliculitis, primary cutaneous marginal zone B-cell lymphoma (MALT
lymphoma) and cutaneous lymphoid hyperplasia. Journal of cutaneous pathology 42,1:6-15.
Kushekhar K, van den Berg A, Nolte I, et al. (2014). Genetic associations in classical hodgkin
lymphoma: a systematic review and insights into susceptibility mechanisms. Cancer Epidemiology,
Biomarkers & Prevention 23,12:2737-2747.
Ondrejka SL and Hsi ED. (2015). Pathology of B-cell lymphomas: diagnosis and biomarker
discovery. Cancer Treatment & Research 165,27-50.
Porrata LF, Inwards DJ, Ansell SM, et al. (2015). Infused autograft lymphocyte to monocyte ratio
predicts survival in classical Hodgkin lymphoma. Journal of Blood Medicine 6,45-53.
Riihijarvi S, Fiskvik I, Taskinen M, et al. (2015). Prognostic influence of macrophages in patients with
diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica
100,2:238-245.
Roth P, Keller A, Hoheisel JD, et al. (2015). Differentially regulated miRNAs as prognostic
biomarkers in the blood of primary CNS lymphoma patients. European journal of cancer 51,3:382390.
Treetipsatit J, Metcalf RA, Warnke RA, et al. (2015). Large B-cell lymphoma with T-cell-rich
background and nodules lacking follicular dendritic cell meshworks: description of an
insufficiently recognized variant. Human pathology 46,1:74-83.
Zhang S, Yu X, Zheng Y, et al. (2014). Value of fine needle aspiration cell blocks in the diagnosis
and classification of lymphoma. International Journal of Clinical & Experimental Pathology 7,11:77177725.
Prognosis, Survival & Risk Factors
Chiu BC and Hou N. (2015). Epidemiology and etiology of non-hodgkin lymphoma. Cancer
Treatment & Research 165,1-25.
4
5
Kreher S, Strehlow F, Martus P, et al. (2015). Prognostic impact of intraocular involvement in
primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. Annals of Hematology 94,3:409414.
Mounier M, Bossard N, Belot A, et al. (2015). Trends in excess mortality in follicular lymphoma at a
population level. European journal of haematology 94,2:120-129.
Nishishinya MB, Pereda CA, Munoz-Fernandez S, et al. (2015). Identification of lymphoma predictors
in patients with primary Sjogren's syndrome: a systematic literature review and meta-analysis.
Rheumatology international 35,1:17-26.
Petrich AM, Helenowski IB, Bryan LJ, et al. (2015). Factors predicting survival in peripheral T-cell
lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. British
journal of haematology 168,5:708-718.
van den Broek EC, Oerlemans S, Nijziel MR, et al. (2015). Impact of active surveillance, chlorambucil,
and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands.
Annals of Hematology 94,1:45-56.
Radiotherapy & Imaging
Cheah CY, Hofman MS, Seymour JF, et al. (2015). The utility and limitations of (18)Ffluorodeoxyglucose positron emission tomography with computed tomography in patients with
primary mediastinal B-cell lymphoma: single institution experience and literature review. Leukemia
& lymphoma 56,1:49-56.
Evens AM and Kostakoglu L. (2014). The role of FDG-PET in defining prognosis of Hodgkin
lymphoma for early-stage disease. Blood 124,23:3356-3364.
Ha CS, Hodgson DC, Advani R, et al. (2014). ACR appropriateness criteria follow-up of Hodgkin
lymphoma. Journal of the American College of Radiology 11,11:1026-1033.e3.
Haque W, Voong KR, Shihadeh F, et al. (2014). Radiation therapy is an effective modality in the
treatment of mantle cell lymphoma, even in heavily pretreated patients. Clinical lymphoma, myeloma
& leukemia 14,6:474-479.
Lu Q, Zhang H, Wang WP, et al. (2015). Primary non-Hodgkin's lymphoma of the liver: sonographic
and CT findings. Hepatobiliary & Pancreatic Diseases International 14,1:75-81.
Maraldo MV and Specht L. (2014). A decade of comparative dose planning studies for early-stage
Hodgkin lymphoma: what can we learn?. International journal of radiation oncology, biology, physics
90,5:1126-1135.
Petersen PM, Aznar MC, Berthelsen AK, et al. (2015). Prospective phase II trial of image-guided
radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncologica
54,1:60-66.
5
6
Sickinger MT, von Tresckow B, Kobe C, et al. (2015). Positron emission tomography-adapted therapy
for first-line treatment in individuals with Hodgkin lymphoma. Cochrane Database of Systematic
Reviews 1,010533.
Thomas K, Karem el-R, Michael W, et al. (2014). Three-dimensional texture analysis of contrast
enhanced CT images for treatment response assessment in Hodgkin lymphoma: comparison with
F-18-FDG PET. Medical physics 41,12:121904.
Wang L, Xia ZJ, Lu Y, et al. (2015). Prophylactic cervical lymph node irradiation provides no benefit
for patients of stage IE extranodal natural killer/T cell lymphoma, nasal type. Medical Oncology
32,1:320.
Woolf DK, Kuhan H, Shoffren O, et al. (2015). Outcomes of primary lymphoma of the ocular adnexa
(orbital lymphoma) treated with radiotherapy. Clinical Oncology (Royal College of Radiologists)
27,3:153-159.
Zhou X, Lu K, Geng L, et al. (2014). Utility of PET/CT in the diagnosis and staging of extranodal
natural killer/T-cell lymphoma: a systematic review and meta-analysis. Medicine 93,28:e258.
Special Populations
Fukano R, Mori T, Kobayashi R, et al. (2015). Haematopoietic stem cell transplantation for relapsed
or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan. British
journal of haematology 168,4:557-563.
Garfin PM, Link MP, Donaldson SS, et al. (2015). Improved outcomes after autologous bone marrow
transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years
experience at a single institution. Biology of Blood & Marrow Transplantation 21,2:326-334.
Hocking J, Schwarer AP, Gasiorowski R, et al. (2014). Excellent outcomes for adolescents and adults
with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the
FRALLE-93 pediatric protocol. Leukemia & lymphoma 55,12:2801-2807.
Molina TJ, Canioni D, Copie-Bergman C, et al. (2014). Young patients with non-germinal center Bcell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus
rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des
Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. Journal of Clinical
Oncology 32,35:3996-4003.
Pieters RS, Wagner H, Baker S, et al. (2014). The impact of protocol assignment for older
adolescents with hodgkin lymphoma. Frontiers in Oncology 4,317.
Trippett TM, Schwartz CL, Guillerman RP, et al. (2015). Ifosfamide and vinorelbine is an effective
reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a
children's oncology group report. Pediatric Blood & Cancer 62,1:60-64
6
7
Supportive Care & Symptom Management
Colombo R, Gallipoli P and Castelli R. (2014). Thrombosis and hemostatic abnormalities in
hematological malignancies. Clinical lymphoma, myeloma & leukemia 14,6:441-450.
Orvain C, Moles-Moreau MP, Francois S, et al. (2015). Miconazole mucoadhesive buccal tablet in
high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis.
Supportive Care in Cancer 23,2:359-364.
Stienen JJ, Ottevanger PB, Wennekes L, et al. (2015). Development and Evaluation of an Educational
E-Tool to Help Patients With Non-Hodgkin's Lymphoma Manage Their Personal Care Pathway.
JMIR Research Protocols 4,1:e6.
Transplantation
Aldoss I and Nademanee A. (2015). Allogeneic Hematopoietic Cell Transplantation in NonHodgkin's Lymphomas. Cancer Treatment & Research 165,329-344.
Al-Malki MM, Castillo JJ, Sloan JM, et al. (2014). Hematopoietic cell transplantation for plasmablastic
lymphoma: a review. Biology of Blood & Marrow Transplantation 20,12:1877-1884.
Eapen M, Logan BR, Horowitz MM, et al. (2015). Bone marrow or peripheral blood for reducedintensity conditioning unrelated donor transplantation. Journal of Clinical Oncology 33,4:364-369.
Hubel K, de la Rubia J, Azar N, et al. (2015). Current status of haematopoietic autologous stem cell
transplantation in lymphoid malignancies: a European perspective. European journal of
haematology 94,1:12-22.
Kato K, Choi I, Wake A, et al. (2014). Treatment of patients with adult T cell leukemia/lymphoma with
cord blood transplantation: a Japanese nationwide retrospective survey. Biology of Blood & Marrow
Transplantation 20,12:1968-1974.
Kokolo MB, Fergusson D, O'Neill J, et al. (2014). Effectiveness and safety of thiotepa as conditioning
treatment prior to stem cell transplant in patients with central nervous system lymphoma.
Leukemia & lymphoma 55,12:2712-2720.
Loirat M, Chevallier P, Leux C, et al. (2015). Upfront allogeneic stem-cell transplantation for patients
with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a
single center. Annals of Oncology 26,2:386-392.
Lukenbill J and Hill B. (2015). Relapsed/refractory diffuse large B-cell lymphoma: review of the
management of transplant-eligible patients. Leukemia & lymphoma 56,2:293-300.
Mei M, Wondergem MJ, Palmer JM, et al. (2014). Autologous transplantation for transformed nonHodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. Biology of
Blood & Marrow Transplantation 20,12:2072-2075.
Rajabi B and Sweetenham JW. (2015). Mantle cell lymphoma: observation to transplantation.
Therapeutic Advances in Hematology 6,1:37-48.
7
8
Reddy NM and Perales MA. (2014). Stem cell transplantation in Hodgkin lymphoma. Hematology Oncology Clinics of North America 28,6:1097-1112.
Sauter CS, Chou JF, Papadopoulos EB, et al. (2014). A prospective study of an alemtuzumab
containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk
and advanced lymphoid malignancies. Leukemia & lymphoma 55,12:2739-2747.
Singavi AK, Harrington AM and Fenske TS. (2015). Post-transplant Lymphoproliferative Disorders.
Cancer Treatment & Research 165,305-327.
Wei J, Xu J, Cao Y, et al. (2015). Allogeneic stem-cell transplantation for peripheral T-cell
lymphoma: a systemic review and meta-analysis. Acta Haematologica 133,2:136-144.
Welch MR, Sauter CS, Matasar MJ, et al. (2015). Autologous stem cell transplant in recurrent or
refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and
cyclophosphamide. Leukemia & lymphoma 56,2:361-367.
Please note that the journal articles you are accessing are subject to the terms and conditions imposed
by the publisher, so there will be a limit on the number of articles an individual may download or print from
a single issue of a journal. You can consult your local NHSGGC library with any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin:
OVID MEDLINE, SIGN, NICE and Healthcare Improvement Scotland
8